Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen

Alemtuzumab, fludarabine, and melphalan reduced-intensity conditioning (RIC) regimens are increasingly used for the hematopoietic cell transplantation (HCT) of pediatric and young adult patients with nonmalignant diseases. Early experience suggests that these regimens are associated with good surviv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Biol Blood Marrow Transplant
Main Authors: Marsh, Rebecca A., Rao, Marepalli B., Gefen, Aharon, Bellman, Denise, Mehta, Parinda A., Khandelwal, Pooja, Chandra, Sharat, Jodele, Sonata, Myers, Kasiani C., Grimley, Michael, Dandoy, Christopher, El-Bietar, Javier, Kumar, Ashish R., Leemhuis, Tom, Zhang, Kejian, Bleesing, Jack J., Jordan, Michael B., Filipovich, Alexandra H., Davies, Stella M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4603747/
https://ncbi.nlm.nih.gov/pubmed/25865646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2015.04.009
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados